CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 6, 2023, at 10:30 a.m. ET. This event highlights the company’s focus on transformative gene-based medicines for serious diseases.
A live webcast will be available on the company's Investors website, with an archived replay accessible for 14 days post-event. CRISPR Therapeutics utilizes its proprietary CRISPR/Cas9 platform to develop treatments across various disease areas, including oncology and rare diseases, in collaboration with leading partners.
- None.
- None.
ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at http://ir.crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
When is CRISPR Therapeutics' fireside chat at the Cowen Health Care Conference?
How can I watch the CRISPR Therapeutics fireside chat?
What is the focus of CRISPR Therapeutics?
How long will the webcast of the fireside chat be available?
What disease areas does CRISPR Therapeutics target?
